Encompass Health (EHC) 2026 stock analysis: America's largest inpatient rehabilitation hospital (IRF) network, aging-population volume growth, the new-hospital and bed-expansion pipeline, scale advantages, the pure-play shift after the 2022 Enhabit spinoff, and the Medicare reimbursement and clinical-labor risks that decide the margin.
HSIC (Henry Schein) 2026 stock outlook. A deep qualitative look at the world's largest dental and medical distribution moat, razor-and-blade recurring consumables, own-brand margin expansion and specialty technology growth versus thin distribution margins, the 2023 cyberattack, activist pressure, and slow organic growth.
Charles River Laboratories (CRL) 2026 stock analysis: the three-pillar preclinical CRO model spanning research models, DSA safety assessment, and CDMO manufacturing, the razor-and-consumable repeat-demand engine, leverage to a recovering biotech funding cycle, NHP primate supply and regulatory risk, and a peer comparison against IQVIA, ICON, Medpace, and Inotiv.
Il-Yang Pharmaceutical (KOSPI 007570) 2026 stock outlook. A deep look at its self-developed novel drugs Noltec (anti-ulcer) and Supect (leukemia targeted therapy), the P-CAB anti-ulcer competition with K-CAB and Fexuclue, Russia export exposure, vaccine and API business, and the structural risk of leaning on a narrow pipeline.
MEDP (Medpace Holdings) 2026 stock outlook. A qualitative deep dive into the founder-led, single-integrated full-service CRO built for small and mid-cap biotech, its high margins and book-to-bill engine, and why net new business awards and backlog swing with the biotech funding cycle, benchmarked against IQVIA, ICON, and Charles River.
Revvity (RVTY) 2026 stock analysis: the PerkinElmer rebrand, a razor-blade recurring-revenue model across Diagnostics and Life Sciences, the newborn-screening franchise moat, and the China VBP and biotech-funding risks that move the story.
Teleflex (TFX) 2026 stock analysis: recurring single-use device revenue across catheters, vascular access, and UroLift, the planned separation of Urology, Acute Care and OEM, the BIOTRONIK vascular deal, UroLift's growth debate, and margins funding deleveraging.
A practical 2026 guide to medical malpractice (physician professional liability) insurance cost in the U.S.: what drives premiums by specialty and state, claims-made vs occurrence policies, tail and nose coverage when you switch or retire, consent-to-settle clauses, per-claim vs aggregate limits, and concrete ways to lower what you pay without leaving yourself exposed.
Daewon Pharmaceutical (KOSPI 003220) 2026 analysis: the Pelubi incrementally modified drug, Coldaewon squeeze-pouch cold medicine, hypertension and diabetes combination drugs, health-supplement expansion, versus drug-price cuts, generic competition, and R&D cost pressure.
LH (Labcorp) 2026 stock outlook. A qualitative deep dive into the clinical-lab duopoly with Quest, the economies-of-scale moat, hospital outreach lab acquisitions as a growth engine, diagnostic volume and reimbursement dynamics, residual CRO exposure after the Fortrea spin-off, dividends, and valuation.
Cardinal Health (CAH) 2026 stock outlook. A qualitative deep dive into the Big-3 drug-distribution oligopoly moat, razor-thin toll-road margins, generics sourcing scale, GLP-1 and specialty volume tailwinds, the GMPD turnaround, and the multi-year opioid-settlement tail.
Viatris (VTRS) 2026 stock outlook. A qualitative deep dive into the Pfizer Upjohn-Mylan merger, the debt paydown and dividend story, brand-revenue decline offset by complex generics and biosimilars, EpiPen's fading pricing power, and the key risks.
Cencora (COR, formerly AmerisourceBergen) 2026 stock analysis: the big-three pharma distribution oligopoly, razor-thin margins on enormous volume, specialty and GLP-1 tailwinds, opioid settlement drag, and Walgreens customer concentration risk.
SD Biosensor (KOSPI 137310) 2026 stock analysis: normalizing revenue after the COVID rapid-test boom, the Meridian Bioscience acquisition, a large cash pile and capital allocation, POCT and molecular diagnostics diversification, and the Abbott/Roche competitive landscape.
InBody (KOSDAQ 041830) 2026 stock analysis for global investors: the world's leading body composition analyzer brand, B2B install base at hospitals and gyms, consumables and subscription recurring revenue, high overseas sales, net-cash balance sheet, and the FX, growth, and new-business risks.
Nano-X Imaging (NNOX) 2026 stock analysis: cold-cathode Nanox.ARC digital tomosynthesis, pay-per-scan imaging-as-a-service model, Nanox.AI, FDA and deployment execution risk, past short-seller controversy, cash burn, and the traits of a high-volatility no-dividend small cap.
Doximity (DOCS) 2026 stock analysis: the LinkedIn-for-doctors network moat, dependence on pharma and health-system marketing budgets, high FCF margins and net cash, DocsGPT AI tools, premium valuation risk, and a no-dividend capital allocation strategy.
BAX Baxter International stock outlook 2026. A qualitative look at the post-Vantive business mix, hospital capex sensitivity in Healthcare Systems & Technologies, competition from Fresenius, B. Braun and Becton Dickinson, the dividend track record, and the deleveraging story.
ResMed (NYSE: RMD) stock analysis — AirSense 11 platform, Philips recall windfall locked in, GLP-1 impact with real adherence data, Brightree/MatrixCare SaaS margin lift. TTM revenue $5.54B, FCF $1.75B. Bull case, bear case, and where we stand.
WBA Walgreens Boots Alliance stock analysis for 2026. Dividend cut context, VillageMD restructuring, PBM margin pressure, CVS competition, debt management, and bull/base/bear scenarios for dividend investors considering recovery plays.
Merck (MRK) 2026 stock analysis: Keytruda's 2028 patent cliff, Winrevair growth, $112.30 price, 3% dividend, analyst targets, and US investor tax strategy.
Pfizer (PFE) 2026 stock analysis: $26.48 price, 6.5% dividend yield, Seagen pipeline, patent cliff risks, and 12-month price targets for US investors.